A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors (CAMELLIA-TIMI)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02019264 |
Recruitment Status
:
Active, not recruiting
First Posted
: December 24, 2013
Last Update Posted
: November 6, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cardiovascular Disease High Cardiovascular Risk Obesity Overweight Type 2 Diabetes | Drug: APD356-Lorcaserin hydrochloride Drug: Placebo | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 12000 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors |
Actual Study Start Date : | January 2014 |
Estimated Primary Completion Date : | September 2018 |
Estimated Study Completion Date : | November 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: APD356 10 mg
APD356 10 mg twice daily
|
Drug: APD356-Lorcaserin hydrochloride
APD356 10 mg twice daily
|
Placebo Comparator: Placebo
Placebo twice daily
|
Drug: Placebo
Placebo twice daily
|
- Time from randomization to first occurrence of Major Adverse Cardiovascular Events (MACE) [ Time Frame: Up to 5 years ]MACE events include: myocardial infarction, stroke and cardiovascular (CV) death
- Time from randomization to conversion to type 2 diabetes mellitus (T2DM) for subjects without any type of diabetes at Baseline [ Time Frame: Baseline, and specified timepoints up to 5 years ]
- Time from randomization to first occurrence of MACE+ [ Time Frame: Up to 5 years ]MACE+ events include: myocardial infarction, stroke, CV death, and hospitalization due to unstable angina, heart failure, or any coronary revascularization
- Time from randomization to event of each component of MACE+ [ Time Frame: Up to 5 years ]
- Time from randomization to event of all-cause mortality [ Time Frame: Up to 5 years ]
- Time from randomization to event of new onset renal impairment or worsening existing renal impairment in subjects with T2DM at Baseline [ Time Frame: Up to 5 years ]New onset renal impairment or worsening existing renal impairment include the first occurrence of microalbuminuria, macroalbuminuria, worsening of albuminuria, newly developed CKD, or worsening of CKD, doubling of serum creatinine, or any of the following: ESRD, renal transplant, and renal death.
- Time from randomization to event of improvement in renal function [ Time Frame: Up to 5 years ]
- Change from Baseline in HbA[1c] at 6 months in subjects with T2DM at Baseline [ Time Frame: Baseline and 6 months ]
- The proportion of subjects who meet FDA-defined valvulopathy in echocardiographically determined heart valve changes [ Time Frame: Baseline and 1 year ]Comparison between lorcaserin HCl and placebo will be made at 1 year.
- The percent change from Baseline in echocardiographically-determined pulmonary arterial systolic pressure [ Time Frame: Baseline and 1 year ]Comparison between lorcaserin HCl and placebo will be made at 1 year.
- Time to conversion to normal glucose homeostasis [ Time Frame: Baseline and 1 year ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
- BMI greater than or equal to 27 kg/m^2
- Subjects able and willing to comply with a reduced-calorie diet and an increased physical activity program
-
Age greater than or equal to 40 years with established CV disease as defined by one of the following:
- History of documented MI or ischemic stroke
- History of peripheral artery disease
- History of revascularization (coronary, carotid, or peripheral artery)
- Significant unrevascularized coronary arterial stenosis
OR
Age greater than or equal to 55 years for women or greater than or equal to 50 years for men who have T2DM without established CV disease plus at least one of the following CV risk factors:
- Hypertension, or currently receiving therapy for documented hypertension
- Dyslipidemia, or currently taking prescription lipid-lowering therapy for documented dyslipidemia
- Calculated creatinine clearance greater than or equal to 30 to less than or equal to 60 mL/min per the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
- High hsCRP
- Urinary albumin-to-creatinine ratio (ACR) greater than or equal to 30 ug/mg
Subjects with T2DM may have a pre-existing or new diagnosis of T2DM. A new diagnosis of T2DM (ie, discovered at Screening) should be based on the 2013 American Diabetes Association (ADA) guidelines.
All T2DM subjects must have an HbA[1c] less than 10% at Screening. If subjects are being treated, or upon diagnosis need to be treated with antidiabetic agents, the T2DM treatment regimen must be stable for at least 3 months prior to randomization.
Exclusion Criteria
- Moderate or greater symptoms of congestive cardiac failure (New York Heart Association [NYHA] class III or IV)
- Known left ventricular (LV) ejection fraction less than 20%
- Moderate or greater symptoms of pulmonary hypertension (PH)
- Known severe valvular disease Moderate renal impairment, severe renal impairment, or end stage renal disease (ESRD) (calculated creatinine clearance less than 30 mL/min per the CKD-EPI equation based on ideal body weight)
- Severe hepatic impairment
- Use of other products intended for weight loss including prescription drugs, over-the-counter (OTC) drugs, and herbal preparations
- Use of more than one other serotonergic drug
- Use of drugs known to increase the risk for cardiac valvulopathy prior to Screening including, but not limited to: cyproheptadine, amoxapine, TCAs, mirtazapine, pergolide, ergotamine, methysergide, cabergoline
- History or evidence of clinically significant disease (e.g., malignancy, cardiac, respiratory, gastrointestinal, renal or psychiatric disease)
- Use of lorcaserin HCl prior to Screening or hypersensitivity to lorcaserin HCl or any of the excipients
- Planned bariatric surgery
- Females must not be breastfeeding or pregnant

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02019264

Responsible Party: | Eisai Inc. |
ClinicalTrials.gov Identifier: | NCT02019264 History of Changes |
Other Study ID Numbers: |
APD356-G000-401 2013-000324-34 ( EudraCT Number ) |
First Posted: | December 24, 2013 Key Record Dates |
Last Update Posted: | November 6, 2017 |
Last Verified: | November 2017 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Keywords provided by Eisai Inc.:
Diabetes Cardiovascular Disease Multiple Cardiovascular Risk Factors Obesity |
Overweight MACE Conversion to Diabetes |
Additional relevant MeSH terms:
Diabetes Mellitus Diabetes Mellitus, Type 2 Cardiovascular Diseases Overweight Glucose Metabolism Disorders |
Metabolic Diseases Endocrine System Diseases Body Weight Signs and Symptoms |